117 related articles for article (PubMed ID: 2867388)
1. Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.
Cantwell B; Harris AL
Lancet; 1986 Jan; 1(8473):165-6. PubMed ID: 2867388
[No Abstract] [Full Text] [Related]
2. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
Cantwell BM; Harris AL
Br Med J (Clin Res Ed); 1987 Feb; 294(6570):467-9. PubMed ID: 3103730
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
Tan TT; Alzaid AA; Sutcliffe N; Gardner MD; Thomson JA; Boyle IT
Postgrad Med J; 1988 Mar; 64(749):224-7. PubMed ID: 3174541
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
Grutters JC; Hermus AR; de Mulder PH; Beex LV
Breast Cancer Res Treat; 1993; 25(3):277-81. PubMed ID: 8369528
[TBL] [Abstract][Full Text] [Related]
5. Parenteral diphosphonates for treating malignant hypercalcemia.
Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
Cancer; 1981 Oct; 48(8):1922-5. PubMed ID: 6456809
[TBL] [Abstract][Full Text] [Related]
6. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Mannix KA; Carmichael J; Harris AL; Cantwell BM
Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
[TBL] [Abstract][Full Text] [Related]
7. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
Sawyer N; Newstead C; Drummond A; Cunningham J
Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615
[TBL] [Abstract][Full Text] [Related]
8. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Sims EC; Rogers PB; Besser GM; Plowman PN
Clin Oncol (R Coll Radiol); 1998; 10(6):407-9. PubMed ID: 9890546
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Ralston SH; Alzaid AA; Gardner MD; Boyle IT
Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
[TBL] [Abstract][Full Text] [Related]
10. [Results of using Aredia for hypercalcemia in oncology patients].
Lichinitser MR; Vyshinskaia GV; Kupchan DZ; Liubimova NV
Ter Arkh; 1993; 65(9):80-1. PubMed ID: 8303606
[No Abstract] [Full Text] [Related]
11. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
Nesković-Konstantinović Z; Mitrović L; Petrović J; Stamatović L; Ristović Z
Support Care Cancer; 1995 Nov; 3(6):422-4. PubMed ID: 8564348
[TBL] [Abstract][Full Text] [Related]
12. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy-associated hypercalcaemia.
Stevens MJ
Med J Aust; 1987 Mar; 146(5):261-4. PubMed ID: 3821622
[TBL] [Abstract][Full Text] [Related]
14. Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation.
Cohen AI; Koeller J; Davis TE; Citrin DL
Cancer Treat Rep; 1981; 65(7-8):651-3. PubMed ID: 6454484
[No Abstract] [Full Text] [Related]
15. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hypercalcemia of malignancy with intermittent single infusions of 3-amino-1-hydroxypropylidene-1, 1-biphosphonate (APD).
Rischin D; Bishop JF
Aust N Z J Med; 1988 Aug; 18(5):736-7. PubMed ID: 3245828
[No Abstract] [Full Text] [Related]
18. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy.
Jung A
Am J Med; 1982 Feb; 72(2):221-6. PubMed ID: 6460442
[TBL] [Abstract][Full Text] [Related]
19. Treatment of severe hypercalcaemia with mithramycin and aminohydroxypropylidene bisphosphonate.
Ralston SH; Gallacher SJ; Dryburgh FJ; Cowan RA; Boyle IT
Lancet; 1988 Jul; 2(8605):277. PubMed ID: 2899259
[No Abstract] [Full Text] [Related]
20. Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
Cömlekçi A; Biberoglu S; Hekimsoy Z; Okan I; Pişkin O; Sekeroglu B; Alakavuklar M
Intern Med; 1998 Apr; 37(4):396-7. PubMed ID: 9630201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
